AZ and Daiichi Sankyo’s breast cancer drug delays progression in advanced diseaseAstraZeneca had to ask shareholders for $3.5 billion in extra cash to finance an R&D tie-up with Daiichi Share XAZ and Daiichi Sankyo’s breast cancer drug delays progression in advanced diseasehttps://pharmaphorum.com/news/az-daiichi-sankyos-breast-cancer-drug-delays-progression-in-advanced-disease/
Mylan and Biocon launch Herceptin biosimilar in USMylan and Biocon have launched their Herceptin biosimilar Ogivri in the US, the second challenger to Roche’s breast Share XMylan and Biocon launch Herceptin biosimilar in UShttps://pharmaphorum.com/news/mylan-and-biocon-launch-herceptin-biosimilar-in-us/
NICE backs Ibrance for breast cancer via Cancer Drugs FundPfizer’s Ibrance has been approved for use by the NHS in England as a second-line treatment for advanced Share XNICE backs Ibrance for breast cancer via Cancer Drugs Fundhttps://pharmaphorum.com/news/nice-backs-ibrance-for-breast-cancer-via-cancer-drugs-fund/
Daiichi Sankyo takes Seattle Genetics to court as battle over breast cancer drug escalatesBig-selling drugs often spark legal bunfights as companies squabble over who did what during the development process and Share XDaiichi Sankyo takes Seattle Genetics to court as battle over breast cancer drug escalateshttps://pharmaphorum.com/news/daiichi-sankyo-takes-seattle-genetics-to-court-as-battle-over-breast-cancer-drug-escalates/
Seattle Genetics plans to file breast cancer drug tucatinibSeattle Genetics has announced plans to file its breast cancer drug tucatinib after the drug met targets in Share XSeattle Genetics plans to file breast cancer drug tucatinibhttps://pharmaphorum.com/news/seattle-genetics-plans-to-file-breast-cancer-drug/
AZ/Daiichi’s possible breast cancer blockbuster gets fast US reviewThe FDA has granted a priority review for AstraZeneca and Daiichi Sankyo’s potential breast cancer blockbuster trastuzumab deruxtecan, Share XAZ/Daiichi’s possible breast cancer blockbuster gets fast US reviewhttps://pharmaphorum.com/news/fda-grants-priority-review-for-trastuzumab-deruxtecan/
NICE says ‘no’ to regular NHS funding for Roche’s Tecentriq in TNBCNICE has said Roche’s Tecentriq (atezolizumab) should not get regular NHS funding in first draft guidance as a Share XNICE says ‘no’ to regular NHS funding for Roche’s Tecentriq in TNBChttps://pharmaphorum.com/news/nice-says-no-to-regular-nhs-funding-for-roches-tecentriq-in-tnbc/
Merck & Co hopes for foothold in early TNBC after Keytruda trial winMerck & Co has unveiled data from its immunotherapy Keytruda that could allow it to gain a foothold Share XMerck & Co hopes for foothold in early TNBC after Keytruda trial winhttps://pharmaphorum.com/news/merck-co-hopes-for-foothold-in-early-tnbc/
Tecentriq beats rivals to EU breast cancer marketRoche has claimed approval in Europe for Tecentriq as a therapy for hard-to-treat triple-negative breast cancer (TNBC), ahead Share XTecentriq beats rivals to EU breast cancer markethttps://pharmaphorum.com/news/tecentriq-beats-rivals-to-eu-breast-cancer-market/
